SEVEN SEAS ORIGINAL PURE COD LIVER OIL CAPSULES

Active substance: RETINOL

View full screen / Print PDF » Download PDF ⇩

Transcript
SUMMARY OF PRODUCT CHARACTERISTICS

1

NAME OF THE MEDICINAL PRODUCT
Seven Seas Cod Liver Oil Capsules
Seven Seas Original Pure Cod Liver Oil Capsules

2

QUALITATIVE AND QUANTITATIVE COMPOSITION
Active Constituents
Cod Liver Oil with vitamins A, D & E
*
containing:
Vitamin A (Retinol)
Vitamin D3 (Colecalciferol)
Vitamin E (Alpha Tocopherol Acetate)
Eicosapentaenoic Acid (EPA)
Docosahexaenoic Acid (DHA)


3

Quantity per Capsule
320 mg

670iu
67iu
0.3iu
22.4mg minimum
19.2mg minimum

Cod Liver Oil complies with the current BP/Ph.Eur monograph for Cod
Liver Oil Type B with the exception of the vitamin content

PHARMACEUTICAL FORM
Capsule

4

CLINICAL PARTICULARS

4.1

Therapeutic indications
a)
Treatment of combined vitamins A, D and E deficiencies.
b)

Combined vitamins A, D and E and Polyunsaturates supplement to the
diet during childhood and in adults with very poor dietary status.

c)

Traditional remedy in the symptomatic relief of muscular and joint
stiffness and aches.

4.2

Posology and method of administration
For mild to moderate deficiency states:
1-3 capsules three times a day
depending on the age of the patient and the severity of the deficiency.
Treatment of the deficiency should be continued usually between 2 weeks - 2
months until the deficiency state is corrected.
As a dietary supplement:

Adults and children over 6 years old - 1-2
capsules three times a day before meals.

Women who are pregnant, lactating or likely to become pregnant - 1 capsule
three times a day.
Do not exceed the stated dose.
To be taken by oral administration.

4.3

Contraindications
- Hypersensitivity to the active substances or to any of the excipients listed in
section 6.1
- Hypercalcaemia
- Hypervitaminoses A, D and E
4.4
Special warnings and precautions for use
Do not take other supplements of Vitamin A and D whilst taking this product.
Benefits from Cod Liver Oil supplementation in malabsorption syndromes are
unlikely.
Omega-3 fatty acids may have antithrombotic activity at high doses and in
patients susceptible to bleeding. Therefore, they should be given with caution
to patients with haemorrhagic disorders or to those receiving anticoagulants or
other drugs affecting coagulation.
There is some evidence to suggest that fish oil supplements may adversely
affect patients with aspirin-sensitive asthma.
Caution is required in hepatic impairment, particularly if receiving high doses.
It is advisable that patients with hepatic impairment do not receive high doses.
4.5

Interaction with other medicinal products and other forms of interaction
Thiazide diuretics with vitamin D may raise calcium levels.
Oestrogen contraceptive pills can raise plasma levels of vitamin A.
In view of a potential effect on bleeding time and platelet aggregation (See Section
4.4), great care should be exercised in patients on concomitant anti-coagulation

therapy or receiving other drugs which may affect coagulation factors, e.g aspirin,
warfarin, cephalosporin.

4.6

Fertility, pregnancy and lactation
Seven Seas Cod Liver Oil capsules should only be used after the consultation
with a physician when planning a pregnancy, during pregnancy and lactation.
The recommended dosage must not be exceeded.
Large doses of vitamin A (exceeding 10,000 IU) have been found to be
teratogenic if administered during the first trimester of pregnancy.

4.7

Effects on ability to drive and use machines
None

4.8

Undesirable effects
Vitamin excess can be harmful but a very large overdose of this product would
be needed to produce ill effects.
As most undesirable effects are based on post-marketing spontaneous
reporting, precise frequency estimation is not possible.
- Gastrointestinal disorders, particularly at high doses, e.g. eructation, fishy
after-taste, nausea, vomiting, abdominal pain, constipation, diarrhoea
- Moderate increases in hepatic transaminases have been reported in patients
with hypertriglyceridaemia
- Skin reactions, e.g. acne, eczema and rash
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal
product is important. It allows continued monitoring of the benefit/risk
balance of the medicinal product. Healthcare professionals are asked to report
any suspected adverse reactions via:
Yellow Card Scheme
Tel: Freephone 0808 100 3352 (available between 10 am – 2 pm Monday –
Friday)
Website: www.mhra.gov.uk/yellowcard

4.9

Overdose

Vitamin A toxicity generally presents as irritability, vomiting, loss of appetite and
skin changes.
Vitamin D toxicity leads to disturbing of calcium metabolism and calcification of soft
tissues including the lungs and kidneys.
The benefit of gastric decontamination is uncertain. Consider activated charcoal
(charcoal dose: 50 g for adults; 1 g/kg for children) only if the patient presents within
1 hour of ingestion of 1.5 mg/kg (5000 iu/kg) or more vitamin A. Other symptomatic
and supportive measures should be provided when indicated. Hepatic, renal, cardiac
and fluid electrolyte status should be carefully monitored.

5

PHARMACOLOGICAL PROPERTIES

5.1

Pharmacodynamic properties
The Vitamin A and D content of Cod Liver Oil ensures that normal dietary
requirements are met and that Vitamin A and D deficiency states are corrected.

5.2

Pharmacokinetic properties
The essential fatty acids, Eicosapentaenoic Acid (EPA) and Docosahexaenoic
Acid (DHA), found in Cod Liver Oil, undergo beta oxidation, EPA is a
precursor of the ‘3’ series of prostaglandins and in a cascade reaction can lead
to the production of thrombozane A3 and prostacyclin PG13.
Precise data on the rate of turnover of EPA and DHA in lipids of nervous
tissue have not been determined.

5.3

Preclinical safety data
There are no preclinincal data of relevance which are additional to those
already included in other sections of the SPC.

6

PHARMACEUTICAL PARTICULARS

6.1

List of excipients
Gelatin
Glycerin
Vegetable Lecithin

Vegetable Oil
Water

6.2

Incompatibilities
None known.

6.3

Shelf life
36 months

6.4

Special precautions for storage
Store under cool dry condition, away from sunlight and direct heat.

6.5

Nature and contents of container
White polypropylene tub with polypropylene screw cap fitted with bore seal
containing 30, 60, 120 250 and 500 capsules or triangular shaped, clear
plastic bottles, with a ROPP metal cap, EPE wad containing 250 & 500
capsules. Packed in individual cartons.

6.6

Special precautions for disposal
No specific instructions required.

7

MARKETING AUTHORISATION HOLDER
SEVEN SEAS LIMITED
HEDON ROAD
MARFLEET
HULL
HU9 5NJ
UNITED KINGDOM

8

MARKETING AUTHORISATION NUMBER(S)
PL 01932/0259

9

DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
04/06/2007

10

DATE OF REVISION OF THE TEXT
20/10/2013

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web4)